Caremel Romain, Albouy Baptiste, De Fourmestraux Aude, Tanneau Yves, Grise Philippe
Service de Chirurgie Urologique, CHU Charles Nicolle, Rouen France.
Prog Urol. 2007 Jun;17(4):796-800. doi: 10.1016/s1166-7087(07)92295-2.
Botulinum toxin was first used in urology in the field of neuro-urology as treatment for detrusor-sphincter dyssynergia and incontinence due to neurogenic overactive bladder. Its action has now been clearly demonstrated and it is now widely used for the treatment of neurogenic overactive bladder. Can botulinum toxin also constitute an effective treatment for benign prostatic hyperplasia (BPH)? Intraprostatic botulinum toxin injections have been shown to have a significant clinical and urodynamic efficacy by acting on both the static and dynamic components of BPH. The advantages of botulinum toxin are its ease of use, the absence of any reported adverse effects and its prolonged duration of action. Well conducted, prospective, controlled studies on larger sample sizes must now be performed to confirm these preliminary results. This review of the literature presents the preliminary results of intraprostatic botulinum toxin injection supporting its use in the treatment of symptomatic benign prostatic hyperplasia.
肉毒杆菌毒素最初在神经泌尿学领域用于治疗逼尿肌-括约肌协同失调以及神经源性膀胱过度活动症所致的尿失禁。如今其作用已得到明确证实，并且已广泛应用于神经源性膀胱过度活动症的治疗。肉毒杆菌毒素能否也构成良性前列腺增生（BPH）的有效治疗方法呢？前列腺内注射肉毒杆菌毒素已显示出通过作用于BPH的静态和动态成分而具有显著的临床和尿动力学疗效。肉毒杆菌毒素的优点是使用方便、未报告任何不良反应且作用持续时间长。现在必须进行设计良好、前瞻性、对照且样本量更大的研究以证实这些初步结果。这篇文献综述展示了前列腺内注射肉毒杆菌毒素的初步结果，支持其用于治疗有症状的良性前列腺增生。
